ArticlePloS one2012
Comparative proteomics of inner membrane fraction from carbapenem-resistant Acinetobacter baumannii with a reference strain.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 78 citations in OpenAlex.
- Proteomic Insights into Antimicrobial Resistance Mechanisms in Human-Associated Bacterial Pathogens.Microbial ecology · 2026Review
- Carbapenem-induced β-lactamase-isoform expression trends in Acinetobacter baumannii.Scientific reports · 2024Article
- Epitope mapping ofHeliyon · 2023Article
- Outer Membrane Porins Contribute to Antimicrobial Resistance in Gram-Negative Bacteria.Microorganisms · 2023Review
- A novel strategy to characterize the pattern of β-lactam antibiotic-induced drug resistance in Acinetobacter baumannii.Scientific reports · 2023Article
- Investigation of Peptidoglycan-Associated Lipoprotein ofInfection and immunity · 2023Article
- Antibiotic Resistance Diagnosis in ESKAPE Pathogens-A Review on Proteomic Perspective.Diagnostics (Basel, Switzerland) · 2023Review
- A novel strategy to characterize the pattern of β-lactam antibiotic-induced drug resistance in Acinetobacter baumannii.Research square · 2023Article
- CRISPR-Cas in Acinetobacter baumannii Contributes to Antibiotic Susceptibility by Targeting EndogenousMicrobiology spectrum · 2022Article
- iTRAQ-Based Quantitative Proteomic Analysis of Acinetobacter baumannii under Hypoxia and Normoxia Reveals the Role of OmpW as a Virulence Factor.Microbiology spectrum · 2022Article
- Structure of ATP synthase from ESKAPE pathogenScience advances · 2022Article
- Ceftazidime-avibactam based combinations against carbapenemase producingComputational and structural biotechnology journal · 2022Article
- Proteomic Analyses ofFrontiers in cellular and infection microbiology · 2021Article
- Lon Protease Has Multifaceted Biological Functions inJournal of bacteriology · 2019Article
- Molecular insight into the therapeutic potential of phytoconstituents targeting protein conformation and their expression.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2019Review
- Anti-outer Membrane Vesicle Antibodies Increase Antibiotic Sensitivity of Pan-Drug-ResistantFrontiers in microbiology · 2019Article
- Molecular mechanism of antimicrobial activity of chlorhexidine against carbapenem-resistant Acinetobacter baumannii.PloS one · 2019Article
- Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii.Scientific reports · 2018Article
- Rationale and design of an inhibitor of RecA protein as an inhibitor of Acinetobacter baumannii.The Journal of antibiotics · 2018Article
- Outer membrane vesicles from β-lactam-resistant Escherichia coli enable the survival of β-lactam-susceptible E. coli in the presence of β-lactam antibiotics.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii has been identified by the Infectious Diseases Society of America as one of the six pathogens that cause majority of hospital infections. Increased resistance of A.baumannii even to the latest generation of β-lactams like carbapenem is an immediate threat to mankind. As inner-membrane fraction plays a significant role in survival of A.baumannii, we investigated the inner-membrane fraction proteome of carbapenem-resistant strain of A.baumannii using Differential In-Gel Electrophoresis (DIGE) followed by DeCyder, Progenesis and LC-MS/MS analysis. We identified 19 over-expressed and 4 down-regulated proteins (fold change>2, p<0.05) in resistant strain as compared to reference strain. Some of the upregulated proteins in resistant strain and their association with carbapenem resistance in A.baumannii are: i) β-lactamases, AmpC and OXA-51: cleave and inactivate carbapenem ii) metabolic enzymes, ATP synthase, malate dehydrogenase and 2-oxoglutarate dehydrogenase: help in increased energy production for the survival and iii) elongation factor Tu and ribosomal proteins: help in the overall protein production. Further, entry of carbapenem perhaps is limited by controlled production of OmpW and low levels of surface antigen help to evade host defence mechanism in developing resistance in A.baumannii. Present results support a model for the importance of proteins of inner-membrane fraction and their synergistic effect in the mediation of resistance of A.baumannii to carbapenem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.